Group 1 - Multiple fund managers express optimism for the equity market in 2026, highlighting investment opportunities in AI technology, consumption, and innovative pharmaceuticals [1] - The market is expected to transition from a valuation-driven to a dual-driven model of profit and valuation, with a healthy valuation structure currently in place [1] - The Chinese economy is shifting from a real estate-driven growth model to an innovation-driven one, with infrastructure and high-tech industries taking over [2] Group 2 - The supply-side pressure in the manufacturing sector is expected to ease by 2026, leading to improved profitability for companies [3] - The AI technology sector is still in a "big infrastructure era," with long-term opportunities outweighing short-term risks [4] - The consumption sector is anticipated to experience a turning point, driven by rising resident income expectations and supportive monetary policies [4] Group 3 - The innovative pharmaceutical sector is expected to have significant growth potential in 2026, with many products entering critical clinical phases that could enhance market confidence [5] - Investment strategies will focus on optimizing competition in traditional consumption and selecting high-quality new consumption stocks with strong fundamentals [4][5]
关于明年A股 基金经理最新研判
Zhong Guo Zheng Quan Bao·2025-12-23 15:14